Market Research Logo

Uveitis- Market Insights, Epidemiology, and Market Forecast-2028

DelveInsight’s ‘Uveitis- Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Uveitis in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Uveitis from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028
Uveitis - Disease Understanding and Treatment Algorithm
The DelveInsight Uveitis market report gives a thorough understanding of the Uveitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Uveitis in the US, Europe, and Japan.
Uveitis
The Uveitis epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Uveitis in 7MM, Total Diagnosed Prevalence of Uveitis in 7MM, Gender-specific Diagnosed Prevalence of Uveitis, Age-specific Diagnosed Prevalence of Uveitis, Type Specific Diagnosed Prevalence of Uveitis, Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location, and Grade-specific Diagnosed Prevalence of Uveitis) scenario of Uveitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to DelveInsight, the total number of diagnosed prevalent population of Uveitis in 7MM was found to be approximately 737,800 in the year 2017.

Uveitis Drug Chapters
This segment of the Uveitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current management of uveitis solely depends on corticosteroids, immunosuppressants, and biologics. Corticosteroids are recommended as first-line of therapies for the treatment of uveitis. The approved and upcoming therapies that fall under this category includes Iluvien, EGP-437, and Suprachoroidal CLS-TA. Corticosteroids accounts for the 65.44% of the total Uveitis market in 2017. Immunosuppressants are the second-line of treatment therapy. The appropriate treatment and choice of immunosuppressive therapy of Uveitis depend on both the extent and severity of the inflammatory process. Biologic response modifiers, or so-called biologics, are the relatively new medications studied and used for the treatment of noninfectious uveitis and other ocular inflammatory diseases. Biologic therapy can be an alternative in patients with inadequate response to or tolerance of conventional immunotherapy.
The horizon currently appears very bright, given the many therapeutic agents and approaches for uveitis and ocular inflammatory diseases. Different classes of agents, from calcineurin inhibitors to mTOR inhibitors and IL inhibitors, among others, are being evaluated. In addition, delivery systems such as iontophoresis will also allow novel methods of safe and effective administration of pharmacologic agents. Hopefully, such efforts will lead to therapeutic options for our patients in the near future.

Launch of emerging therapies, such as Sirolimus (for Non-Infectious Uveitis of the Posterior Segment (NIU-PS)), EGP-437 (for Non-Infectious Anterior Uveitis), Sarilumab (for Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)), Suprachoroidal CLS-TA(Triamcinolone Acetonide) (for Macular edema associated with non-infectious uveitis), LFG316 (Non-infectious Intermediate Uveitis; Non-infectious Posterior Uveitis; Non-infectious Panuveitis), LME636 ( Anterior Acute Uveitis) shall further create a positive impact on the market.
Apart from the pharmacological therapies few companies are working in the development of gene therapy which can provide a cure to the disease.
Uveitis Market Outlook
The Uveitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Uveitis in 7MM was found to be approximately USD 1027.0 million in 2017 and is expected to increase from 2017-2028.
Uveitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Uveitis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Uveitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Uveitis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Uveitis Infections market
• Organize sales and marketing efforts by identifying the best opportunities for Uveitis market
• To understand the future market competition in the Uveitis market.


1. Key Insights
2. Uveitis Market Overview At A Glance
2.1. Market Share (%) Distribution Of Uveitis In 2017
2.2. Market Share (%) Distribution Of Uveitis In 2028
3. Disease Background And Overview: Uveitis
3.1. Introduction
3.2. Classification Of Uveitis
3.3. International Uveitis Study Group (Iusg) Clinical Classification Of Uveitis
3.4. The Standardization Of Uveitis Nomenclature (Sun) Working Group
3.5. Symptoms Of Uveitis
3.6. Pathophysiology
3.7. Etiology Of Uveitis
3.8. Diagnosis Of Uveitis
3.8.1. American Academy Of Family Physicians
4. Epidemiology And Patient Population
4.1. Key Findings
4.2. Prevalent Population Of Uveitis In The 7mm
4.3. Diagnosed Prevalent Population Of Uveitis In The 7mm
4.4. Type Specific Diagnosed Prevalent Population Of Uveitis In The 7mm
5. United States-epidemiology Of Uveitis
5.1. Assumptions And Rationale
5.2. Total Prevalent Population Of Uveitis In The United States
5.3. Diagnosed Prevalent Population Of Uveitis In The United States
5.4. Gender-specific Diagnosed Prevalent Population Of Uveitis In United States
5.5. Age-specific Diagnosed Prevalent Population Of Uveitis In United States
5.6. Type Specific Diagnosed Prevalent Population Of Uveitis In United States
5.7. Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location
5.7.1. Diagnosed Prevalent Cases Of Anterior Noninfectious Uveitis (Aniu) In The United States
5.7.2. Diagnosed Prevalent Cases Of Nonanterior Niu (Posterior Segment) Or Nipu In The United States
5.8. Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In The United States
6. Eu-5 Epidemiology Of Uveitis
6.1. Germany
6.1.1. Assumptions And Rationale
6.1.2. Prevalent Population Of Uveitis In Germany
6.1.3. Diagnosed Prevalent Population Of Uveitis In Germany
6.1.4. Gender Specific Diagnosed Prevalence Of Uveitis In Germany
6.1.5. Age Group Specific Diagnosed Prevalence Of Uveitis In Germany
6.1.6. Type Specific Diagnosed Prevalence Of Uveitis In Germany
6.1.7. Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location
6.1.8. Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Germany
6.2. France
6.2.1. Assumptions And Rationale
6.2.2. Prevalent Population Of Uveitis In France
6.2.3. Diagnosed Prevalent Population Of Uveitis In France
6.2.4. Gender Specific Diagnosed Prevalence Of Uveitis In France
6.2.5. Age Specific Diagnosed Prevalence Of Uveitis In France
6.2.6. Type Specific Diagnosed Prevalence Of Uveitis In France
6.2.7. Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location
6.2.8. Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In France
6.3. Italy
6.3.1. Assumptions And Rationale
6.3.2. Prevalent Population Of Uveitis In The Italy
6.3.3. Diagnosed Prevalent Population Of Uveitis In Italy
6.3.4. Gender Specific Diagnosed Prevalence Of Uveitis In Italy
6.3.5. Age Specific Diagnosed Prevalence Of Uveitis In Italy
6.3.6. Type Specific Diagnosed Prevalence Of Uveitis In Italy
6.3.7. Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location
6.3.8. Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Italy
6.4. Spain
6.4.1. Assumptions And Rationale
6.4.2. Prevalent Population Of Uveitis In The Spain
6.4.3. Diagnosed Prevalent Population Of Uveitis In Spain
6.4.4. Gender Specific Diagnosed Prevalence Population Of Uveitis In Spain
6.4.5. Age Specific Diagnosed Prevalence Of Uveitis In Spain
6.4.6. Type Specific Diagnosed Prevalence Of Uveitis In Spain
6.4.7. Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Spain
6.4.8. Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Spain
6.5. United Kingdom
6.5.1. Assumptions And Rationale
6.5.2. Prevalent Population Of Uveitis In The Uk
6.5.3. Diagnosed Prevalent Population Of Uveitis In United Kingdom
6.5.4. Gender Specific Diagnosed Prevalence Of Uveitis In Uk
6.5.5. Age Specific Diagnosed Prevalence Of Uveitis In Uk
6.5.6. Type Specific Diagnosed Prevalence Of Uveitis In Uk
6.5.7. Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In The Uk
6.5.8. Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In The Uk
7. Japan
7.1. Assumptions And Rationale
7.2. Prevalent Population Of Uveitis In The Japan
7.3. Diagnosed Prevalent Population Of Uveitis In The Japan
7.4. Gender Specific Prevalence Of Uveitis In Japan
7.5. Age Specific Prevalence Of Uveitis In Japan
7.6. Type Specific Prevalence Of Uveitis In Japan
7.7. Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Japan
7.8. Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Japan
8. Treatment Of Uveitis
8.1. Treatment Algorithm
8.2. First Line Of Therapy: Corticosteroids
8.3. Second Line Of Therapy: Immunosuppressants
8.4. Third Line Of Therapy: Biologics
8.5. Guidance On Non-corticosteroid Systemic Immunomodulatory Therapy In Noninfectious Uveitis: Fundamentals Of Care For Uveitis (Focus) Initiative
9. Unmet Needs
10. Marketed Drugs
10.1. Key Cross Competition
10.2. Durezol: Sirion Therapeutics
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Advantages & Disadvantages
10.2.4. Safety And Efficacy
10.2.5. Product Profile
10.3. Triesence: Novartis
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Advantages & Disadvantages
10.3.4. Safety And Efficacy
10.3.5. Product Profile
10.4. Retisert: Valeant Pharmaceuticals International Inc
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Advantages & Disadvantages
10.4.4. Safety
10.4.5. Efficacy
10.4.6. Product Profile
10.5. Ozurdex: Allergan Plc
10.5.1. Drug Description
10.5.2. Regulatory Milestones
10.5.3. Advantages & Disadvantages
10.5.4. Efficacy
10.5.5. Safety
10.5.6. Product Profile
10.6. Humira: Abbvie Inc.
10.6.1. Drug Description
10.6.2. Regulatory Milestones
10.6.3. Advantages & Disadvantages
10.6.4. Safety And Efficay
10.6.5. Product Profile
10.7. Yutiq: Eyepoint Pharmaceuticals
10.7.1. Product Description
10.7.2. Clinical Development
10.7.3. Advantages & Disadvantages
10.7.4. Safety And Efficacy
10.7.5. Product Profile
10.8. Tobradex: Alcon Laboratories
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Product Profile
10.9. Acthar: Mallinckrodt
10.9.1. Product Description
10.9.2. Other Developmental Activities
10.9.3. Advantages And Disadvantages
10.9.4. Safety And Efficacy
10.9.5. Product Profile
10.10. Iluvien: Alimera Sciences
10.10.1. Product Description
10.10.2. Other Developmental Activities
10.10.3. Clinical Development
10.10.4. Clinical Trials Information
10.10.5. Safety And Efficacy
10.10.6. Product Profile
11. Emerging Drugs Analysis
11.1. Key Cross Competition
11.2. Adx-102: Aldeyra Therapeutics Inc.
11.2.1. Product Description
11.2.2. Advantages & Disadvantages
11.2.3. Clinical Development
11.2.4. Safety And Efficacy
11.2.5. Product Profile
11.3. Sirolimus: Santen
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Advantages & Disadvantages
11.3.4. Clinical Development
11.3.5. Safety And Efficacy
11.3.6. Product Profile
11.4. Egp-437: Eyegate Pharmaceuticals
11.4.1. Product Description
11.4.2. Regulatory Milestones
11.4.3. Advantages & Disadvantages
11.4.4. Clinical Development
11.4.5. Safety And Efficacy
11.4.6. Product Profile
11.5. Suprachoroidal Cls-ta: Clearside Biomedical, Inc.
11.5.1. Product Description
11.5.2. Clinical Development
11.5.3. Safety And Efficacy
11.5.4. Product Profile
11.6. Sarilumab: Sanofi Aventis
11.6.1. Product Description
11.6.2. Product Development Activities
11.6.3. Advantages And Disadvantages
11.6.4. Clinical Development
11.6.5. Safety And Efficacy
11.6.6. Product Profile
11.7. Lme636 (Ocs-02): Oculis Pharma
11.7.1. Product Description
11.7.2. Other Development Activities
11.7.3. Clinical Development
11.7.4. Safety And Efficacy
11.7.5. Product Profile
11.8. Lfg316: Novartis
11.8.1. Product Description
11.8.2. Other Development Activities
11.8.3. Clinical Development
11.8.4. Safety And Efficacy
11.8.5. Product Profile
11.9. Abatacept (Orenica): Bristol-myers Squibb Company
11.9.1. Product Description
11.9.2. Clinical Development
11.9.3. Safety And Efficacy
11.9.4. Product Profile
11.10. Eys606: Eyevensys
11.10.1. Product Description
11.10.2. Other Development Activities
11.10.3. Clinical Development
11.10.4. Safety And Efficacy
11.10.5. Product Profile
12. Uveitis: 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size Of Uveitis In The 7mm
12.3. Market Size Of Uveitis By Therapies In The 7mm
13. United States: Market Outlook
13.1. Total Market Size Of Uveitis
13.2. Uveitis Market Size By Therapies
14. Eu5: Market Outlook
14.1. Germany Market Size
14.1.1. Total Market Size Of Uveitis
14.1.2. Uveitis Market Size By Therapies
14.2. France Market Size
14.2.1. Total Market Size Of Uveitis
14.2.2. Uveitis Market Size By Therapies
14.3. Italy Market Size
14.3.1. Total Market Size Of Uveitis
14.3.2. Uveitis Market Size By Therapies
14.4. Spain Market Size
14.4.1. Total Market Size Of Uveitis
14.4.2. Uveitis Market Size By Therapies
14.5. United Kingdom Market Size
14.5.1. Total Market Size Of Uveitis
14.5.2. Uveitis Market Size By Therapies
15. Japan: Market Outlook
15.1. Japan: Market Size
15.1.1. Total Market Size Of Uveitis
15.1.2. Uveitis Market Size By Therapies
16. Market Drivers
17. Market Barriers
18. Appendix
19. Report Methodology
19.1. Sources Used
20. Delveinsight Capabilities
21. Disclaimer
22. About Delveinsight
Table 1 Iusg Clinical Classification Of Uveitis
Table 2 The Sun Working Group Anatomic Classification Of Uveitis
Table 3 The Sun Working Group Descriptors Of Uveitis
Table 4 The Sun Working Group Grading Scheme For Anterior Chamber Cells
Table 5 The Sun Working Group Grading Scheme For Anterior Chamber Cells
Table 6 Key Recommendations For Practice
Table 7 Region-wise Prevalent Population Of Uveitis (2017–2028)
Table 8 Diagnosed Prevalent Population Of Uveitis (2017–2028)
Table 9 Type Specific Diagnosed Prevalent Population Of Uveitis In The 7mm (2017–2028)
Table 10 Total Prevalent Population Of Uveitis In Us (2017–2028)
Table 11 Total Diagnosed Prevalent Population Of Uveitis In Us (2017–2028)
Table 12 Gender Specific Diagnosed Prevalent Population Of Uveitis In The Us (2017–2028)
Table 13 Age-specific Diagnosed Prevalent Population Of Uveitis In The Us (2017–2028)
Table 14 Type-specific Diagnosed Prevalent Population Of Uveitis In Us (2017–2028)
Table 15 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In The United States (2017–2028)
Table 16 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In The United States (2017–2028)
Table 17 Prevalent Population Of Uveitis In Germany (2017–2028)
Table 18 Diagnosed Prevalent Population Of Uveitis In Germany (2017–2028)
Table 19 Gender Specific Diagnosed Prevalent Population Of Uveitis In Germany (2017–2028)
Table 20 Age Specific Diagnosed Prevalent Population Of Uveitis In Germany (2017–2028)
Table 21 Type Specific Diagnosed Prevalent Population Of Uveitis In Germany (2017–2028)
Table 22 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Germany (2017–2028)
Table 23 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Germany (2017–2028)
Table 24 Prevalent Population Of Uveitis In France (2017–2028)
Table 25 Diagnosed Prevalent Population Of Uveitis In France (2017–2028)
Table 26 Gender Specific Diagnosed Prevalent Population Of Uveitis In France (2017–2028)
Table 27 Age Specific Diagnosed Prevalent Population Of Uveitis In France (2017–2028)
Table 28 Type Specific Diagnosed Prevalent Population Of Uveitis In France (2017–2028)
Table 29 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In France (2017–2028)
Table 30 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In France (2017–2028)
Table 31 Prevalent Population Of Uveitis In Italy (2017–2028)
Table 32 Diagnosed Prevalent Population Of Uveitis In Italy (2017–2028)
Table 33 Gender Specific Diagnosed Prevalent Population Of Uveitis In Italy (2017–2028)
Table 34 Age Specific Diagnosed Prevalent Population Of Uveitis In Italy (2017–2028)
Table 35 Type Specific Diagnosed Prevalent Population Of Uveitis In Italy (2017–2028)
Table 36 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Italy (2017–2028)
Table 37 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Italy (2017–2028)
Table 38 Prevalent Population Of Uveitis In Spain (2017–2028)
Table 39 Diagnosed Prevalent Population Of Uveitis In Spain (2017–2028)
Table 40 Gender Specific Diagnosed Prevalent Population Of Uveitis In Spain (2017–2028)
Table 41 Age Specific Diagnosed Prevalent Population Of Uveitis In Spain (2017–2028)
Table 42 Type Specific Diagnosed Prevalent Population Of Uveitis In Spain (2017–2028)
Table 43 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Spain (2017–2028)
Table 44 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Spain (2017–2028)
Table 45 Prevalent Population Of Uveitis In Uk (2017–2028)
Table 46 Diagnosed Prevalent Population Of Uveitis In Uk (2017–2028)
Table 47 Gender Specific Diagnosed Prevalent Population Of Uveitis In Uk (2017–2028)
Table 48 Age Specific Prevalent Population Of Uveitis In Uk (2017–2028)
Table 49 Type Specific Diagnosed Prevalent Population Of Uveitis In Uk (2017–2028)
Table 50 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Uk (2017–2028)
Table 51 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Uk (2017–2028)
Table 52 Prevalent Population Of Uveitis In Japan (2017–2028)
Table 53 Diagnosed Prevalent Population Of Uveitis In Japan (2017–2028)
Table 54 Gender Specific Prevalent Population Of Uveitis In Japan (2017–2028)
Table 55 Age Specific Prevalent Population Of Uveitis In Japan (2017–2028)
Table 56 Type Specific Prevalent Population Of Uveitis In Japan (2017–2028)
Table 57 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Japan (2017–2028)
Table 58 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Japan (2017–2028)
Table 59 First Line Of Therapy Of The Treatment Of Uveitis, 2019
Table 60 Marketed Drugs For Uveitis
Table 61 Tobradex, Clinical Trial Description, 2019
Table 62 Emerging Drugs Analysis
Table 63 Adx-102, Clinical Trial Description, 2019
Table 64 Sirolimus, Clinical Trial Description, 2019
Table 65 Egp 437, Clinical Trial Description, 2019
Table 66 Suprachoroidal Cls-ta, Clinical Trial Description, 2019
Table 67 Sarilumab, Clinical Trial Description, 2019
Table 68 Lme636, Clinical Trial Description, 2019
Table 69 Lfg316, Clinical Trial Description, 2019
Table 70 Abatacept, Clinical Trial Description, 2019
Table 71 Eys606, Clinical Trial Description, 2019
Table 72 Market Size Of Uveitis By Region In Usd Million (2017–2028)
Table 73 Market Size Of Uveitis By Therapies In The Seven Major Market (7mm),In Usd Million (2017–2028)
Table 74 Market Size Of Uveitis In The United States, Usd Million (2017–2028)
Table 75 The United States Uveitis Market Size By Therapies In Usd Million (2017–2028)
Table 76 Market Size Of Uveitis In Germany, Usd Million (2017–2028)
Table 77 Market Size Of Uveitis By Therapies In Germany, In Usd Million (2017–2028)
Table 78 Market Size Of Uveitis In France, Usd Million (2017–2028)
Table 79 Market Size Of Uveitis By Therapies In France, In Usd Million (2017–2028)
Table 80 Market Size Of Uveitis In Italy, Usd Million (2017–2028)
Table 81 Market Size Of Uveitis By Therapies In Italy, In Usd Million (2017–2028)
Table 82 Market Size Of Uveitis In Spain, Usd Million (2017–2028)
Table 83 Market Size Of Uveitis By Therapies In Spain, In Usd Million (2017–2028)
Table 84 Market Size Of Uveitis In Uk, Usd Million (2017–2028)
Table 85 Market Size Of Uveitis By Therapies In The United Kingdom, In Usd Million (20172028)
Table 86 Market Size Of Uveitis In Japan, Usd Million (2017–2028)
Table 87 Market Size Of Uveitis By Therapies In The Japan, In Usd Million (2017–2028)
Figure 1 Structure Of Eye
Figure 2 Types Of Uveitis And Affected Area
Figure 3 Classification Of Uveitis
Figure 4 Types Of Uveitis Are Based On The Different Parts Of Eye. Below Are The Four Types
Figure 5 Symptoms Of Uveitis
Figure 6 Pathogenetic Mechanism Of Uveitis
Figure 7 Mechanism Of Antigen Processing And Presentation.
Figure 8 Autoimmune Conditions That Cause Uveitis
Figure 9 Causes Of Uveitis
Figure 10 Diagnosis Algorithm For Uveitis
Figure 11 Prevalent Population Of Uveitis In The 7mm (2017–2028)
Figure 12 Diagnosed Prevalent Population Of Uveitis In The 7mm (2017–2028)
Figure 13 Type Specific Diagnosed Prevalent Population Of Uveitis In The 7mm (2017–2028)
Figure 14 Total Prevalent Population Of Uveitis In United States (2017–2028)
Figure 15 Diagnosed Prevalent Population Of Uveitis In United States (2017–2028)
Figure 16 Gender-specific Diagnosed Prevalent Population Of Uveitis In United States (2017–2028)
Figure 17 Age-specific Diagnosed Prevalent Population Of Uveitis In The United States (2017–2028)
Figure 18 Type Specific Diagnosed Prevalent Population Of Uveitis In The Us (2017–2028)
Figure 19 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In The United States (2017–2028)
Figure 20 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In The United States (2017–2028)
Figure 21 Prevalent Population Of Uveitis In Germany (2017–2028)
Figure 22 Diagnosed Prevalent Population Of Uveitis In Germany (2017–2028)
Figure 23 Gender Specific Diagnosed Prevalent Population Of Uveitis In Germany (2017–2028)
Figure 24 Age Specific Diagnosed Prevalent Population Of Uveitis In Germany (2017–2028)
Figure 25 Type Specific Diagnosed Prevalent Population Of Uveitis In Germany (2017–2028)
Figure 26 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Germany (2017–2028)
Figure 27 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Germany 2017–2028)
Figure 28 Prevalent Population Of Uveitis In France (2017–2028)
Figure 29 Diagnosed Prevalent Population Of Uveitis In France (2017–2028)
Figure 30 Gender Specific Diagnosed Prevalent Population Of Uveitis In France (2017–2028)
Figure 31 Age Specific Diagnosed Prevalent Population Of Uveitis In France (2017–2028)
Figure 32 Type Specific Diagnosed Prevalent Population Of Uveitis In France (2017–2028)
Figure 33 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In France (2017–2028)
Figure 34 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In France (2017–2028)
Figure 35 Prevalent Population Of Uveitis In Italy (2017–2028)
Figure 36 Diagnosed Prevalent Population Of Uveitis In Italy (2017–2028)
Figure 37 Gender Specific Diagnosed Prevalent Population Of Uveitis In Italy (2017–2028)
Figure 38 Age Specific Diagnosed Prevalent Population Of Uveitis In Italy (2017–2028)
Figure 39 Type Specific Diagnosed Prevalent Population Of Uveitis In Italy (2017–2028)
Figure 40 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Italy (2017–2028)
Figure 41 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Italy (2017–2028)
Figure 42 Prevalent Population Of Uveitis & Non-infectious Uveitis (Niu) In Spain (2017–2028)
Figure 43 Diagnosed Prevalent Population Of Uveitis In Spain (2017–2028)
Figure 44 Gender Specific Diagnosed Prevalent Population Of Uveitis In Spain (2017–2028)
Figure 45 Age Specific Diagnosed Prevalent Population Of Uveitis In Spain (2017–2028)
Figure 46 Type Specific Diagnosed Prevalent Population Of Uveitis In Spain (2017–2028)
Figure 47 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Spain (2017–2028)
Figure 48 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Spain (2017–2028)
Figure 49 Prevalent Population Of Uveitis In Uk (2017–2028)
Figure 50 Diagnosed Prevalent Population Of Uveitis In Uk (2017–2028)
Figure 51 Gender Specific Diagnosed Prevalent Population Of Uveitis In Uk (2017–2028)
Figure 52 Age Specific Diagnosed Prevalent Population Of Uveitis In Uk (2017–2028)
Figure 53 Type Specific Diagnosed Prevalent Population Of Uveitis In The Uk (2017–2028)
Figure 54 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In The Uk (2017–2028)
Figure 55 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In The Uk (2017–2028)
Figure 56 Prevalent Population Of Uveitis In Japan (2017–2028)
Figure 57 Diagnosed Prevalent Population Of Uveitis In Japan (2017–2028)
Figure 58 Gender Specific Prevalent Population Of Uveitis In Japan (2017–2028)
Figure 59 Age Specific Prevalent Population Of Uveitis In Japan (2017–2028)
Figure 60 Type Specific Prevalent Population Of Uveitis In Japan (2017–2028)
Figure 61 Diagnosed Prevalence Of Non-infectious Uveitis (Niu) By Anatomical Location In Japan (2017-2028)
Figure 62 Grade-specific Diagnosed Prevalence Of Anterior Noninfectious Uveitis (Aniu) In Japan (2017–2028)
Figure 63 Treatment Regimens
Figure 64 Treatment Algorithm Of Uveitis
Figure 65 Therapeutic Algorithm In Endogenous Anterior Uveitis (Au)
Figure 66 Therapeutic Algorithm In Endogenous Intermediate Uveitis (Iu)
Figure 67 Therapeutic Algorithm In Immune-mediated Posterior Uveítis Or Panuveiti
Figure 68 Management Flowchart For Non-infectious Uveitis
Figure 69 Unmet Needs
Figure 70 Market Size Of Uveitis By Region In Usd Million (2017–2028)
Figure 71 Market Size Of Uveitis By Therapies In The Seven Major Market (7mm), In Usd Million (2017–2028)
Figure 72 Market Size Of Uveitis In The United States, Usd Million (2017–2028)
Figure 73 The United States Uveitis Market Size By Therapies In Usd Million (2017–2028)
Figure 74 Market Size Of Uveitis In Germany, Usd Million (2017–2028)
Figure 75 Market Size Of Uveitis By Therapies In Germany, In Usd Million (2017–2028)
Figure 76 Market Size Of Uveitis In France, Usd Million (2017–2028)
Figure 77 France Uveitis Market Size By Therapies In Usd Million (2017–2028)
Figure 78 Market Size Of Uveitis In Italy, Usd Million (2017–2028)
Figure 79 Italy Uveitis Market Size By Therapies In Usd Million (2017–2028)
Figure 80 Market Size Of Uveitis In Spain, Usd Million (2017–2028)
Figure 81 Spain Uveitis Market Size By Therapies In Usd Million (2017–2028)
Figure 82 Market Size Of Uveitis In United Kingdom, Usd Million (2017–2028)
Figure 83 United Kingdom Uveitis Market Size By Therapies In Usd Million (2017–2028)
Figure 84 Market Size Of Uveitis In Japan, Usd Million (2017–2028)
Figure 85 Japan Uveitis Market Size By Therapies In Usd Million (2017–2028)
Figure 86 Market Drivers Of Uveitis
Figure 87 Market Barriers Of Uveitis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook